This recommendation is not intended to affect treatment with olipudase alfa that was started in the NHS before this guidance was published. People having treatment outside this recommendation may ...

Sanofi now has approval on both sides of the Atlantic for Xenpozyme – its enzyme replacement therapy for rare disease acid sphingomyelinase deficiency (ASMD) – after getting a green light from ...